Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

ClinicalTrials.gov ID: NCT00706862

Public ClinicalTrials.gov record NCT00706862. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to determine whether the combination of talactoferrin, carboplatin and paclitaxel improves progression free survival and overall survival in patients with non-small cell lung cancer compared to the combination of paclitaxel and carboplatin alone

Study identification

NCT ID: NCT00706862
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Agennix; Industry
Enrollment: 1,100 participants

Conditions and interventions

Conditions

Non Small Cell Lung Cancer

Interventions

Talactoferrin Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 31, 2009
Primary completion: May 31, 2015
Completion: Feb 29, 2016
Last update posted: Mar 14, 2012

2009 – 2016

United States locations

U.S. sites: 6
U.S. states: 5
U.S. cities: 6

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Recruiting
Rush University Medical Center	Chicago	Illinois	60612	Withdrawn
Montefiore Medical Center	The Bronx	New York	10467	Recruiting
Duke University Medical Center	Durham	North Carolina	27710	Recruiting
Chattanooga Oncology and Hematology Associates	Chattanooga	Tennessee	37404	Recruiting
Sarah Cannon Research Institute	Nashville	Tennessee	37203	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00706862, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 14, 2012 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00706862 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →